|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
New Guidelines and Novel Treatments for PAH: Taking a Forward-Looking Data Dive Into the Pool of Emerging Therapies
Target Audience
This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).
Program Overview
Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key mo... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
New Guidelines, Emerging Treatments, and Unexpected Patients: Understanding the Challenges of PAH
Target Audience
This activity is designed for nurse practitioners, nurses, and physician assistants who manage patients with or at risk for PAH.
Program Overview
It is a deadly disease and there’s still no cure, but with treatment, survival for patients with pulmonary arterial hypertension (PAH) can be significantly extended. Although rare, nurse practitioners are likely to encounter this cardiopulmonary disorder throughout their careers, and need to be familiar with the multiple dru... |
|
|
WEBINAR: Introduction to Homeopathic Medicines for Veterinary Pharmacists
Overview " Homeopathic medicines have been used for over 200 years in humans, plants, and animals. They have been recognized as drugs by the FDA since 1938 and are easily accessible over-the-counter in all markets. The use of homeopathic medicines continues to grow in popularity, yet many misconceptions still circulate about their efficacy and safety. Many pharmacists lack training on homeopathic medicines, but pharmacists have an obligation to be well-informed about the strengths and lim... |
|
|
WEBINAR: Intro to Anatomy and Physiology and Drug Disposition for Nonhumans
Overview: On March 15, 2021, APhA HOD approved ACVP’s proposal to expand the definition of a “patient” to include both human and non-human species. While this expansion highlights the wide scope of care provided by pharmacists, a paucity in veterinary pharmacotherapy education remains. In two independent surveys, 77% of pharmacists reported that they routinely filled prescriptions for animals. In a 2021, only 26.7% of colleges and schools of pharmacy surveyed responded that veterinary p... |
|